1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Clore, G.M.
Qin, J.
Gronenborn, A.M.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
1
90.00
90.00
90.00
1.000
1.000
1.000
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C3 H7 N O2 S
121.158
y
CYSTEINE
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C5 H11 N O2 S
149.211
y
METHIONINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C11 H12 N2 O2
204.225
y
TRYPTOPHAN
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
UK
Structure
STRUE6
2005
0969-2126
4
613
620
10.1016/S0969-2126(96)00065-2
8736558
The solution structure of human thioredoxin complexed with its target from Ref-1 reveals peptide chain reversal.
1996
UK
Structure
STRUE6
2005
0969-2126
3
289
Solution Structure of Human Thioredoxin in a Mixed Disulfide Intermediate Complex with its Target Peptide from the Transcription Factor NF Kappa B
1995
UK
Structure
STRUE6
2005
0969-2126
2
503
The High-Resolution Three-Dimensional Solution Structures of the Oxidized and Reduced States of Human Thioredoxin
1994
US
Biochemistry
BICHAW
0033
0006-2960
30
2685
High-Resolution Three-Dimensional Structure of Reduced Recombinant Human Thioredoxin in Solution
1991
10.2210/pdb1cqg/pdb
pdb_00001cqg
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
11592.125
THIOREDOXIN
CHAIN A, C35A, C62A, C69A, C73A
1
man
polymer
1404.611
REF-1 PEPTIDE
4.2.99.18
RESIDUES 59 - 71 OF THE P50 SUBUNIT OF NFKB
1
man
polymer
no
no
MVKQIESKTAFQEALDAAGDKLVVVDFSATWCGPAKMIKPFFHSLSEKYSNVIFLEVDVDDAQDVASEAEVKATPTFQFF
KKGQKVGEFSGANKEKLEATINELV
MVKQIESKTAFQEALDAAGDKLVVVDFSATWCGPAKMIKPFFHSLSEKYSNVIFLEVDVDDAQDVASEAEVKATPTFQFF
KKGQKVGEFSGANKEKLEATINELV
A
polypeptide(L)
no
no
PATLKICSWNVDG
PATLKICSWNVDG
B
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
human
Homo
sample
POTENTIAL
9606
Homo sapiens
database_2
pdbx_database_related
pdbx_database_status
pdbx_struct_assembly
pdbx_struct_oper_list
struct_ref_seq_dif
repository
Initial release
Version format compliance
Version format compliance
Database references
Derived calculations
Other
1
0
1996-08-01
1
1
2008-03-24
1
2
2011-07-13
1
3
2021-11-03
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_pdbx_database_related.content_type
_pdbx_database_related.details
_pdbx_database_status.process_site
_struct_ref_seq_dif.details
representative structure
Y
BNL
1996-04-02
REL
REL
THR AT POSITION 74 WAS FOUND BY WOLMAN ET AL., JOURNAL OF
BIOCHEMISTRY 263, 15506 (1988).
35
OTHER REFINEMENT REMARKS:
THE STRUCTURES ARE CALCULATED USING THE HYBRID METRIC
MATRIX DISTANCE GEOMETRY-DYNAMICAL SIMULATED ANNEALING
METHOD DESCRIBED BY: NILGES, M., CLORE, G.M. &
GRONENBORN, A.M. (1988) FEBS LETT 229, 317 - 324.
MODIFIED TO INCORPORATE COUPLING CONSTANT (GARRETT ET AL.
(1994) J. MAGN. RESON SERIES B 104 99 - 103), CARBON
CHEMICAL SHIFT (KUSZEWSKI ET AL. (1995) J. MAGN. RESON.
SERIES B 106, 92 - 96), AND PROTON CHEMICAL SHIFT
(KUSZEWSKI ET AL. (1995) J. MAGN. RESON SERIES B 107,
293 - 297) RESTRAINTS, AND A CONFORMATIONAL DATABASE
POTENTIAL TERM (KUSZEWSKI, GRONENBORN & CLORE (1996)
PROTEIN SCIENCE IN PRESS). ALL STRUCTURAL STATISTICS ARE
GIVEN IN THE REFERENCE.
THE 3D STRUCTURE OF THE HUMAN THIOREDOXIN-NFKB PEPTIDE
COMPLEX IN SOLUTION BY NMR IS BASED ON 3213 EXPERIMENTAL
RESTRAINTS COMPRISING:
2581 STRUCTURE USEFUL INTERPROTON DISTANCE RESTRAINTS
36 RESTRAINTS FOR 18 BACKBONE H-BONDS
321 TORSION ANGLE RESTRAINTS (104 PHI, 76 PSI, 78 CHI1,
AND 30 CHI2 FOR HUMAN THIOREDOXIN, AND 11 PHI,
9 PSI, 9 CHI1, AND 4 CHI2 ANGLES FOR THE REF-1
PEPTIDE
86 HN-HALPHA THREE-BOND COUPLING CONSTANTS
100 13CALPHA AND 97 13CB CHEMICAL SHIFT RESTRAINTS.
442 1H CHEMICAL SHIFT RESTRAINTS (MADE UP OF 113 CAH,
67 METHYL GROUPS AND 262 OTHER NON-EXCHANGEABLE
PROTONS).
THE BREAKDOWN OF THE INTERPROTON DISTANCE RESTRAINTS IS AS
FOLLOWS:
INTRAMOLECULAR HTRX RESTRAINTS:
534 SEQUENTIAL
539 SHORT RANGE (1 < |I-J|<=5)
688 LONG RANGE (|I-J|>5)
682 INTRARESIDUE
INTRAMOLECULAR PEPTIDE RESTRAINTS: 83
INTERMOLECULAR HTRX-NFKB: 55
THE STRUCTURE FOUND IN PDB ENTRY 1CQH IS THE RESTRAINED
MINIMIZED AVERAGE STRUCTURE: (SA)R. THIS IS OBTAINED BY
FIRST AVERAGING THE COORDINATES OF THE INDIVIDUAL 35
DYNAMICAL SIMULATED ANNEALING SA STRUCTURES BEST FITTED TO
RESIDUES 1 - 105 OF HTRX AND RESIDUES 57 - 67 OF THE
PEPTIDE AND SUBJECTING THE RESULTING COORDINATES TO
RESTRAINED MINIMIZATION. THE LAST NUMBER COLUMN IN THIS
SET OF COORDINATES (THE B-FACTOR COLUMN IN X-RAY
STRUCTURES) GIVES THE AVERAGE RMS DIFFERENCE BETWEEN THE
INDIVIDUAL SA STRUCTURES AND THE MEAN STRUCTURE.
MET
1
n
1
MET
1
A
VAL
2
n
2
VAL
2
A
LYS
3
n
3
LYS
3
A
GLN
4
n
4
GLN
4
A
ILE
5
n
5
ILE
5
A
GLU
6
n
6
GLU
6
A
SER
7
n
7
SER
7
A
LYS
8
n
8
LYS
8
A
THR
9
n
9
THR
9
A
ALA
10
n
10
ALA
10
A
PHE
11
n
11
PHE
11
A
GLN
12
n
12
GLN
12
A
GLU
13
n
13
GLU
13
A
ALA
14
n
14
ALA
14
A
LEU
15
n
15
LEU
15
A
ASP
16
n
16
ASP
16
A
ALA
17
n
17
ALA
17
A
ALA
18
n
18
ALA
18
A
GLY
19
n
19
GLY
19
A
ASP
20
n
20
ASP
20
A
LYS
21
n
21
LYS
21
A
LEU
22
n
22
LEU
22
A
VAL
23
n
23
VAL
23
A
VAL
24
n
24
VAL
24
A
VAL
25
n
25
VAL
25
A
ASP
26
n
26
ASP
26
A
PHE
27
n
27
PHE
27
A
SER
28
n
28
SER
28
A
ALA
29
n
29
ALA
29
A
THR
30
n
30
THR
30
A
TRP
31
n
31
TRP
31
A
CYS
32
n
32
CYS
32
A
GLY
33
n
33
GLY
33
A
PRO
34
n
34
PRO
34
A
ALA
35
n
35
ALA
35
A
LYS
36
n
36
LYS
36
A
MET
37
n
37
MET
37
A
ILE
38
n
38
ILE
38
A
LYS
39
n
39
LYS
39
A
PRO
40
n
40
PRO
40
A
PHE
41
n
41
PHE
41
A
PHE
42
n
42
PHE
42
A
HIS
43
n
43
HIS
43
A
SER
44
n
44
SER
44
A
LEU
45
n
45
LEU
45
A
SER
46
n
46
SER
46
A
GLU
47
n
47
GLU
47
A
LYS
48
n
48
LYS
48
A
TYR
49
n
49
TYR
49
A
SER
50
n
50
SER
50
A
ASN
51
n
51
ASN
51
A
VAL
52
n
52
VAL
52
A
ILE
53
n
53
ILE
53
A
PHE
54
n
54
PHE
54
A
LEU
55
n
55
LEU
55
A
GLU
56
n
56
GLU
56
A
VAL
57
n
57
VAL
57
A
ASP
58
n
58
ASP
58
A
VAL
59
n
59
VAL
59
A
ASP
60
n
60
ASP
60
A
ASP
61
n
61
ASP
61
A
ALA
62
n
62
ALA
62
A
GLN
63
n
63
GLN
63
A
ASP
64
n
64
ASP
64
A
VAL
65
n
65
VAL
65
A
ALA
66
n
66
ALA
66
A
SER
67
n
67
SER
67
A
GLU
68
n
68
GLU
68
A
ALA
69
n
69
ALA
69
A
GLU
70
n
70
GLU
70
A
VAL
71
n
71
VAL
71
A
LYS
72
n
72
LYS
72
A
ALA
73
n
73
ALA
73
A
THR
74
n
74
THR
74
A
PRO
75
n
75
PRO
75
A
THR
76
n
76
THR
76
A
PHE
77
n
77
PHE
77
A
GLN
78
n
78
GLN
78
A
PHE
79
n
79
PHE
79
A
PHE
80
n
80
PHE
80
A
LYS
81
n
81
LYS
81
A
LYS
82
n
82
LYS
82
A
GLY
83
n
83
GLY
83
A
GLN
84
n
84
GLN
84
A
LYS
85
n
85
LYS
85
A
VAL
86
n
86
VAL
86
A
GLY
87
n
87
GLY
87
A
GLU
88
n
88
GLU
88
A
PHE
89
n
89
PHE
89
A
SER
90
n
90
SER
90
A
GLY
91
n
91
GLY
91
A
ALA
92
n
92
ALA
92
A
ASN
93
n
93
ASN
93
A
LYS
94
n
94
LYS
94
A
GLU
95
n
95
GLU
95
A
LYS
96
n
96
LYS
96
A
LEU
97
n
97
LEU
97
A
GLU
98
n
98
GLU
98
A
ALA
99
n
99
ALA
99
A
THR
100
n
100
THR
100
A
ILE
101
n
101
ILE
101
A
ASN
102
n
102
ASN
102
A
GLU
103
n
103
GLU
103
A
LEU
104
n
104
LEU
104
A
VAL
105
n
105
VAL
105
A
PRO
59
n
1
PRO
59
B
ALA
60
n
2
ALA
60
B
THR
61
n
3
THR
61
B
LEU
62
n
4
LEU
62
B
LYS
63
n
5
LYS
63
B
ILE
64
n
6
ILE
64
B
CYS
65
n
7
CYS
65
B
SER
66
n
8
SER
66
B
TRP
67
n
9
TRP
67
B
ASN
68
n
10
ASN
68
B
VAL
69
n
11
VAL
69
B
ASP
70
n
12
ASP
70
B
GLY
71
n
13
GLY
71
B
author_defined_assembly
2
dimeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
identity operation
0.0000000000
0.0000000000
0.0000000000
A
O
LYS
3
A
O
LYS
3
A
N
PHE
54
A
N
PHE
54
A
O
ILE
53
A
O
ILE
53
A
N
VAL
24
A
N
VAL
24
A
O
VAL
23
A
O
VAL
23
A
N
PHE
80
A
N
PHE
80
A
O
PHE
77
A
O
PHE
77
A
N
PHE
89
A
N
PHE
89
11
A
A
HE21
H
GLN
ASP
63
64
1.27
14
B
ASN
68
-49.24
-13.16
29
B
ASN
68
-54.31
-5.04
35
B
ASN
68
-49.94
-10.59
35
B
VAL
69
-42.40
153.22
HIGH RESOLUTION SOLUTION NMR STRUCTURE OF MIXED DISULFIDE INTERMEDIATE BETWEEN HUMAN THIOREDOXIN (C35A, C62A, C69A, C73A) MUTANT AND A 13 RESIDUE PEPTIDE COMPRISING ITS TARGET SITE IN HUMAN REF-1 (RESIDUES 59-71 OF THE P50 SUBUNIT OF NFKB), NMR, 31 STRUCTURES
1
N
N
2
N
N
A
LYS
8
A
LYS
8
HELX_P
A
ALA
17
A
ALA
17
1
1
10
A
GLY
33
A
GLY
33
HELX_P
A
PHE
42
A
PHE
42
1
2
10
A
SER
44
A
SER
44
HELX_P
A
LYS
48
A
LYS
48
5
3
5
A
GLN
63
A
GLN
63
HELX_P
A
ALA
69
A
ALA
69
1
4
7
A
LYS
94
A
LYS
94
HELX_P
A
LEU
104
A
LEU
104
1
5
11
disulf
2.030
A
CYS
32
A
SG
CYS
32
1_555
B
CYS
65
B
SG
CYS
7
1_555
COMPLEX (ELECTRON TRANSPORT/PEPTIDE)
COMPLEX, ELECTRON TRANSPORT/PEPTIDE, COMPLEX (ELECTRON TRANSPORT-PEPTIDE) COMPLEX
A
THR
74
A
THR
74
1
A
PRO
75
A
PRO
75
-1.93
A
THR
74
A
THR
74
2
A
PRO
75
A
PRO
75
-2.86
A
THR
74
A
THR
74
3
A
PRO
75
A
PRO
75
-1.98
A
THR
74
A
THR
74
4
A
PRO
75
A
PRO
75
-2.42
A
THR
74
A
THR
74
5
A
PRO
75
A
PRO
75
-1.56
A
THR
74
A
THR
74
6
A
PRO
75
A
PRO
75
-2.35
A
THR
74
A
THR
74
7
A
PRO
75
A
PRO
75
-1.96
A
THR
74
A
THR
74
8
A
PRO
75
A
PRO
75
-3.49
A
THR
74
A
THR
74
9
A
PRO
75
A
PRO
75
-2.39
A
THR
74
A
THR
74
10
A
PRO
75
A
PRO
75
-2.18
A
THR
74
A
THR
74
11
A
PRO
75
A
PRO
75
-2.49
A
THR
74
A
THR
74
12
A
PRO
75
A
PRO
75
-2.91
A
THR
74
A
THR
74
13
A
PRO
75
A
PRO
75
-2.07
A
THR
74
A
THR
74
14
A
PRO
75
A
PRO
75
-2.32
A
THR
74
A
THR
74
15
A
PRO
75
A
PRO
75
-1.71
A
THR
74
A
THR
74
16
A
PRO
75
A
PRO
75
-1.89
A
THR
74
A
THR
74
17
A
PRO
75
A
PRO
75
-2.87
A
THR
74
A
THR
74
18
A
PRO
75
A
PRO
75
-2.46
A
THR
74
A
THR
74
19
A
PRO
75
A
PRO
75
-2.76
A
THR
74
A
THR
74
20
A
PRO
75
A
PRO
75
-2.04
A
THR
74
A
THR
74
21
A
PRO
75
A
PRO
75
-2.27
A
THR
74
A
THR
74
22
A
PRO
75
A
PRO
75
-2.49
A
THR
74
A
THR
74
23
A
PRO
75
A
PRO
75
-2.66
A
THR
74
A
THR
74
24
A
PRO
75
A
PRO
75
-2.18
A
THR
74
A
THR
74
25
A
PRO
75
A
PRO
75
-3.12
A
THR
74
A
THR
74
26
A
PRO
75
A
PRO
75
-2.18
A
THR
74
A
THR
74
27
A
PRO
75
A
PRO
75
-1.57
A
THR
74
A
THR
74
28
A
PRO
75
A
PRO
75
-2.11
A
THR
74
A
THR
74
29
A
PRO
75
A
PRO
75
-2.86
A
THR
74
A
THR
74
30
A
PRO
75
A
PRO
75
-2.50
A
THR
74
A
THR
74
31
A
PRO
75
A
PRO
75
-2.59
A
THR
74
A
THR
74
32
A
PRO
75
A
PRO
75
-2.28
A
THR
74
A
THR
74
33
A
PRO
75
A
PRO
75
-3.04
A
THR
74
A
THR
74
34
A
PRO
75
A
PRO
75
-2.11
A
THR
74
A
THR
74
35
A
PRO
75
A
PRO
75
-3.68
THIO_HUMAN
UNP
1
1
P10599
VKQIESKTAFQEALDAAGDKLVVVDFSATWCGPCKMIKPFFHSLSEKYSNVIFLEVDVDDCQDVASECEVKCMPTFQFFK
KGQKVGEFSGANKEKLEATINELV
APEX1_HUMAN
UNP
2
1
P27695
PKRGKKGAVAEDGDELRTEPEAKKSKTAAKKNDKEAAGEGPALYEDPPDQKTSPSGKPATLKICSWNVDGLRAWIKKKGL
DWVKEEAPDILCLQETKCSENKLPAELQELPGLSHQYWSAPSDKEGYSGVGLLSRQCPLKVSYGIGDEEHDQEGRVIVAE
FDSFVLVTAYVPNAGRGLVRLEYRQRWDEAFRKFLKGLASRKPLVLCGDLNVAHEEIDLRNPKGNKKNAGFTPQERQGFG
ELLQAVPLADSFRHLYPNTPYAYTFWTYMMNARSKNVGWRLDYFLLSHSLLPALCDSKIRSKALGSDHCPITLYLAL
1
104
1CQG
2
105
P10599
A
1
2
105
58
70
1CQG
59
71
P27695
B
2
1
13
1
CYS
engineered mutation
ALA
35
1CQG
A
P10599
UNP
34
35
1
CYS
engineered mutation
ALA
62
1CQG
A
P10599
UNP
61
62
1
CYS
engineered mutation
ALA
69
1CQG
A
P10599
UNP
68
69
1
CYS
engineered mutation
ALA
73
1CQG
A
P10599
UNP
72
73
1
MET
conflict
THR
74
1CQG
A
P10599
UNP
73
74
5
parallel
parallel
anti-parallel
anti-parallel
A
VAL
2
A
VAL
2
A
ILE
5
A
ILE
5
A
ILE
53
A
ILE
53
A
VAL
57
A
VAL
57
A
VAL
23
A
VAL
23
A
PHE
27
A
PHE
27
A
THR
76
A
THR
76
A
LYS
81
A
LYS
81
A
GLN
84
A
GLN
84
A
SER
90
A
SER
90
1
P 1